These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15301999)

  • 1. The clinical implications of aldosterone escape in congestive heart failure.
    Struthers AD
    Eur J Heart Fail; 2004 Aug; 6(5):539-45. PubMed ID: 15301999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
    Struthers AD
    Eur Heart J; 1995 Dec; 16 Suppl N():103-6. PubMed ID: 8682054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
    Mulder P; Mellin V; Favre J; Vercauteren M; Remy-Jouet I; Monteil C; Richard V; Renet S; Henry JP; Jeng AY; Webb RL; Thuillez C
    Eur Heart J; 2008 Sep; 29(17):2171-9. PubMed ID: 18586661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F
    Am J Cardiol; 1993 Jan; 71(3):34A-39A. PubMed ID: 8422003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone in congestive heart failure.
    Soberman JE; Weber KT
    Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of heart failure following myocardial infarction.
    Struthers AD
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii14-6; discussion ii31, ii43-8. PubMed ID: 15831601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
    Pitt B; Stier CT; Rajagopalan S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):164-8. PubMed ID: 14608520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.